Please assess the completion status of the following clinical trial:

Trial Title: Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Eligibility Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Confirmed recurrent Stage IV NSCLC which progressed while on treatment with EGFR TKI~* Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)~* Documented evidence of an EGFR mutation known to be associated with an EGFR TKI sensitivity~* No T790M mutation or small cell transformation including an assessment from tumor biopsy obtained while on or subsequent to the most recent EGFR TKI therapy~* Acceptable laboratory results as indicated by protocol~* Acceptable cardiac function as indicated by protocol~Key Exclusion Criteria:~* Receiving medication that prolongs QT interval, with a risk of causing Torsades de Pointes (TdP) unless ECG meets inclusion criteria while on a stable dose of the medication~* Family history of long corrected QT interval (QTc) syndrome~* Symptomatic central nervous system (CNS) lesions~* Radiation therapy within 2 weeks prior to the first dose of study medication~* Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication~* Concurrent active malignancy requiring systemic treatment~* Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection (e.g., tuberculosis, viral hepatitis, human immunodeficiency virus \[HIV\]), recent (within 6 months) myocardial infarction or unstable angina, congestive heart failure, poorly-controlled hypertension or diabetes, concurrent active malignancy, or psychiatric condition that may interfere with the patient's ability to follow study procedures~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TH-4000 (Tarloxotinib) (Type: EXPERIMENTAL): TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).